Adicet Bio is a biotechnology business based in the US. Adicet Bio shares (ACET) are listed on the NASDAQ and all prices are listed in US Dollars. Adicet Bio employs 132 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.44 |
|---|---|
| 52-week range | $1.39 - $21.87 |
| 50-day moving average | $2.16 |
| 200-day moving average | $5.90 |
| Wall St. target price | $20.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.60 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.44 from 2023-09-27
| 1 week (2023-09-21) | -5.88% |
|---|---|
| 1 month (2023-08-28) | -14.29% |
| 3 months (2023-06-28) | -45.45% |
| 6 months (2023-03-28) | -73.91% |
| 1 year (2022-09-27) | -89.53% |
|---|---|
| 2 years (2021-09-28) | -82.78% |
| 3 years (2020-09-28) | 10.57 |
| 5 years (2018-09-28) | 105.98 |
Valuing Adicet Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adicet Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adicet Bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.82. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adicet Bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Gross profit TTM | $25 million |
|---|---|
| Return on assets TTM | -25.26% |
| Return on equity TTM | -43.26% |
| Profit margin | 0% |
| Book value | $5.55 |
| Market Capitalization | $62.9 million |
TTM: trailing 12 months
We're not expecting Adicet Bio to pay a dividend over the next 12 months.
Adicet Bio's shares were split on a 1:7 basis on 15 September 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adicet Bio shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Adicet Bio shares which in turn could have impacted Adicet Bio's share price.
Over the last 12 months, Adicet Bio's shares have ranged in value from as little as $1.39 up to $21.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adicet Bio's is 1.5802. This would suggest that Adicet Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adicet Bio, Inc. , a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
Everything we know about the Discord IPO, plus information on how to buy in.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing HGGG, with 24-hour and historical pricing before you buy.